title: Suppression of post-vitrectomy lens changes in the rabbit by novel benzopyranyl esters and amides.
abstract: This study reports for the first time a therapeutic modality for the suppression of posterior subcapsular cataract (PSC) formation in an animal model (rabbit) of vitrectomy. This therapeutic modality may also have the potential to attenuate/prevent the high incidence of loss of vision due to cataract formation in patients that undergo vitrectomy. Unilateral, partial vitrectomy was performed on 2.5 month old Dutch Belted rabbits with vitreous replaced by either commercially available BSS((R)) or BSS PLUS((R)) (n=16). Alternatively, vitreous was replaced with a proprietary, modified BSS PLUS((R)) irrigating solution containing 1.25 microM AL-8417 (n=12), 5.0 microM AL-12615 (n=5) or 5.0 microM AL-17052 (n=9). Age matched, non-operated rabbits were used as controls (n=16). Lenses were analysed by correlative structural (light, scanning electron microscopic and three-dimensional computer-assisted drawings) and optical (low power helium-neon laser scan) quality analysis 6 months following surgery. Results demonstrate that vitreous replacement with an irrigating solution that contains the ester-linked benzopyran, AL-8417, the amide-linked benzopyran pro-drug, AL-17052, or its active metabolite, AL-12615, prevented abnormal post-vitrectomy lens growth, or fiber formation. Focal length variability (FLV) assessments (sharpness of focus) confirmed the beneficial drug effects detected morphologically, with FLV being essentially equal to that of age-matched, non-surgical controls. In contrast, lenses of animals with vitreous replaced solely with BSS((R)) or BSS PLUS((R)) exhibited significantly higher FLV than both age-matched controls and animals that underwent vitrectomy with drug-containing irrigating solutions. The ability of AL-8417, AL-17052 and its active metabolite, AL-12615, to suppress vitrectomy-induced posterior lens fiber changes appears to reside in their unique pharmacological profile, acting as antioxidant, anti-inflammatory and cytostatic agents.
authors.affiliation: Department of Ophthalmology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Kuszak
authors.forename: J G
authors.initials: JG
authors.lastname: Sivak
authors.forename: K L
authors.initials: KL
authors.lastname: Moran
authors.forename: S A
authors.initials: SA
authors.lastname: Scheib
authors.forename: W H
authors.initials: WH
authors.lastname: Garner
authors.forename: T L
authors.initials: TL
authors.lastname: Ke
authors.forename: M R
authors.initials: MR
authors.lastname: Hellberg
authors.forename: G
authors.initials: G
authors.lastname: Graff
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001578:Benzopyrans / Q000494:pharmacology*; D005123:Eye / Q000378:metabolism; D006868:Hydrolysis; D007908:Lens, Crystalline / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008855:Microscopy, Electron, Scanning; D011817:Rabbits; D014821:Vitrectomy / Q000009:adverse effects*
chemical_list: D000975:Antioxidants; D001578:Benzopyrans